Company profile

Theranexus specializes in the research and development of therapeutic products for the treatment of diseases affecting the central nervous system. At the end of 2017, the group had one product in Phase II clinical development (THN102; treatment of narcolepsy-related sleep-wake disorders and Parkinson's disease) and 2 products in preclinical development phase (THN101; treatment of neuropathic pain and THN201 for the treatment of neurocognitive disorders in Alzheimer's disease).

Source: Cofisem - Last Update: 03 Jun 2020
Key Executives
Chairman and Chief Executive Officer Franck Mouthon
Deputy CEO Mathieu Charveriat
Administrative & Finance Director Thierry Lambert
Human Resources Director Françoise Vincent-Larrode
Source: Cofisem - Last Update: 02 Jun 2020
Key figures
Millenium 2019 2018 2017 2016 2015
Net sales
Consumed purchases
Payroll 2,353 2,118 1,370 689 542
Operating profit -7,377 -6,990 -2,719 -2,058 -1,116
Income tax -2,038 -1,721 730 583 -605
Net income -5,580 -5,301 -2,115 -1,587 -519
Net consolidated income (Group share) -5,580 -5,301 -2,115 -1,587 -519
Fiscal year end 12.19 12.18 12.17 12.16 12.15
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 03 Jun 2020
Shareholder information
Free float 38,3 %
Auriga Partners 17,7 %
Supernova Invest 13,7 %
Mathieu Charveriat 8,8 %
Franck Mouthon 8,8 %
Sofimac Régions 8,4 %
Kreaxi 4,2 %
Employees 0,10 %
Employees 0,0 %
Source: Theranexus - Last Update: 22 Jul 2020

Financial analysis

Equity research report, in partnership with Morningstar

View Report

Address

Theranexus

Pépinière Laennec 60 Avenue Rockefeller
FR-69008 Lyon
France
Phone number: +33 (0)1 46 54 98 96
Fax: +33
Source: Cofisem - Last Update: 03 Jun 2020

Contact

LAMBERT THIERRY
Phone number: +33 1 46 54 98 96
Source: Theranexus - Last Update: 22 Jul 2020